Kemp Dolliver
Stock Analyst at Brookline Capital
(0.47)
# 4,186
Out of 5,093 analysts
16
Total ratings
33.33%
Success rate
-20.93%
Average return
Main Sectors:
Stocks Rated by Kemp Dolliver
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RNTX Rein Therapeutics | Downgrades: Hold | n/a | $1.45 | - | 1 | Aug 19, 2025 | |
| RADX Radiopharm Theranostics | Initiates: Buy | $18 | $4.23 | +325.53% | 1 | Jul 21, 2025 | |
| LSTA Lisata Therapeutics | Maintains: Buy | $20 → $32 | $2.03 | +1,480.25% | 1 | Jul 15, 2025 | |
| VRCA Verrica Pharmaceuticals | Downgrades: Hold | n/a | $8.27 | - | 2 | Oct 2, 2024 | |
| IBIO iBio, Inc. | Initiates: Buy | $3.6 | $2.22 | +62.16% | 1 | Jul 22, 2024 | |
| DARE Daré Bioscience | Upgrades: Buy | $36 | $1.86 | +1,835.48% | 2 | May 15, 2024 | |
| OTLK Outlook Therapeutics | Upgrades: Buy | $31 | $2.08 | +1,409.62% | 1 | Jan 25, 2024 | |
| LNTH Lantheus Holdings | Initiates: Buy | $100 | $60.88 | +64.26% | 1 | Nov 30, 2023 | |
| EDSA Edesa Biotech | Maintains: Buy | $57 | $1.79 | +3,084.36% | 2 | Oct 12, 2023 | |
| GNLX Genelux | Initiates: Hold | $25 | $4.55 | +449.45% | 1 | May 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $19 | $4.90 | +282.65% | 1 | Jan 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $8 | $0.65 | +1,140.31% | 1 | Oct 21, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $5.65 | $0.69 | +713.07% | 1 | Feb 2, 2022 |
Rein Therapeutics
Aug 19, 2025
Downgrades: Hold
Price Target: n/a
Current: $1.45
Upside: -
Radiopharm Theranostics
Jul 21, 2025
Initiates: Buy
Price Target: $18
Current: $4.23
Upside: +325.53%
Lisata Therapeutics
Jul 15, 2025
Maintains: Buy
Price Target: $20 → $32
Current: $2.03
Upside: +1,480.25%
Verrica Pharmaceuticals
Oct 2, 2024
Downgrades: Hold
Price Target: n/a
Current: $8.27
Upside: -
iBio, Inc.
Jul 22, 2024
Initiates: Buy
Price Target: $3.6
Current: $2.22
Upside: +62.16%
Daré Bioscience
May 15, 2024
Upgrades: Buy
Price Target: $36
Current: $1.86
Upside: +1,835.48%
Outlook Therapeutics
Jan 25, 2024
Upgrades: Buy
Price Target: $31
Current: $2.08
Upside: +1,409.62%
Lantheus Holdings
Nov 30, 2023
Initiates: Buy
Price Target: $100
Current: $60.88
Upside: +64.26%
Edesa Biotech
Oct 12, 2023
Maintains: Buy
Price Target: $57
Current: $1.79
Upside: +3,084.36%
Genelux
May 18, 2023
Initiates: Hold
Price Target: $25
Current: $4.55
Upside: +449.45%
Jan 13, 2023
Initiates: Buy
Price Target: $19
Current: $4.90
Upside: +282.65%
Oct 21, 2022
Assumes: Buy
Price Target: $8
Current: $0.65
Upside: +1,140.31%
Feb 2, 2022
Initiates: Buy
Price Target: $5.65
Current: $0.69
Upside: +713.07%